DAWNZERA Drug Patent Profile
✉ Email this page to a colleague
When do Dawnzera patents expire, and what generic alternatives are available?
Dawnzera is a drug marketed by Ionis Pharms Inc and is included in one NDA. There are five patents protecting this drug.
The generic ingredient in DAWNZERA is donidalorsen sodium. One supplier is listed for this compound. Additional details are available on the donidalorsen sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Dawnzera
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DAWNZERA?
- What are the global sales for DAWNZERA?
- What is Average Wholesale Price for DAWNZERA?
Summary for DAWNZERA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| What excipients (inactive ingredients) are in DAWNZERA? | DAWNZERA excipients list |
| DailyMed Link: | DAWNZERA at DailyMed |
US Patents and Regulatory Information for DAWNZERA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
